Stefan Franzén, PhD

Director
BPM Evidence Statistics, Medical Evidence, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, Sweden

Disclosure information not submitted.

Presentation(s):

• 6G-01 - The ECHO Study: Evaluation of Cloning-Censor-Weighting to assess the effect of time to treatment initiation of single inhaler dual ICS/LABA therapy after a first observed COPD diagnosis in the United States

  Tuesday, August 26, 2025
  1:30 PM - 1:45 PM ET